Mosanna Therapeutics
Redwood City
About Mosanna Therapeutics
Mosanna Therapeutics develops a nighttime nasal spray aimed at treating obstructive sleep apnea (OSA) by enhancing the body’s natural airway control. The company focuses on innovative pharmaceutical solutions to address the challenges associated with sleep-related disorders. By leveraging cutting-edge research, Mosanna Therapeutics aims to improve patient outcomes for those affected by OSA. The company’s commitment to advancing clinical initiatives is evident in its approach to developing effective treatments. Through its novel product, Mosanna Therapeutics seeks to provide a viable option for individuals struggling with this condition, contributing to the broader field of sleep medicine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $80.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2025)
- Website: mosanna.com
- Phone: +1 650 381 9916
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/mosanna-therapeutics-97418 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.